Every Form 4 that Acurx Pharmaceuticals, Inc. (ACXP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals director Carl Sailer received a stock option grant tied to his service on the company’s board. The award covers 2,150 options for Common Stock at an exercise price of $2.36 per share.
The options were granted as part of Acurx’s Director Compensation Policy and will fully vest on April 20, 2027. Following this award, Sailer holds stock options for 2,150 underlying shares, which are scheduled to expire on April 20, 2036.
Acurx Pharmaceuticals director Jack H. Dean received a compensatory stock option award for service on the company’s board. The grant covers 2,150 shares of common stock at an exercise price of $2.36 per share, expiring on April 20, 2036.
The option was granted at no cost and is scheduled to vest in full on April 20, 2027 under Acurx’s Director Compensation Policy. This Form 4 reports an option grant only; it does not show any open‑market purchases or sales of Acurx common stock by the director.
Acurx Pharmaceuticals director James J. Donohue received a stock option grant covering 2,150 shares of common stock as board compensation. The option has an exercise price of $2.36 per share, vests on April 20, 2027, and expires on April 20, 2036. Following the grant, he holds 2,150 stock options directly.
Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.
The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.
Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.
The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock. The options were granted on April 20, 2026 with an exercise price of $2.36 per share and expire on April 20, 2036.
The options vest in 36 equal monthly installments starting on the grant date, meaning the award vests gradually over three years. Following this grant, DeLuccia holds stock options for 37,100 underlying shares directly, with no additional derivative positions shown in this filing.
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.
The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.
Acurx Pharmaceuticals, Inc. reported that its Chief Financial Officer, Robert G. Shawah, received a grant of stock options covering 25,900 shares of common stock on April 20, 2026.
The options have an exercise price of $2.36 per share, expire on April 20, 2036, and vest in 36 equal monthly installments starting on the grant date. After this grant, he holds stock options for 25,900 shares directly as reported in this filing. This is a compensation-related award rather than an open-market share purchase or sale.